Research on CRISPR/system in major cancers and its potential in cancer treatments

Liu, Z; Liao, Zhiwei; Chen, Yan; Zhou, Lihua; Huangting, W; Xiao, Hongtao

doi:10.1007/s12094-020-02450-3

Cited by 4 publications

(5 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, this system suffers from off‐targeting effects that could be overcome using vectors. 247 , 248 , 249 , 250 , 251 , 252 , 253 In this section, we discuss the use of liposomes for the targeted delivery of the CRISPR/Cas9 system in cancer treatment.…”

Section: Liposomes and Gene Deliverymentioning

confidence: 99%

“…In addition to reducing tumor progression, CRISPR/Cas9 system can be applied to elevate drug sensitivity. However, this system suffers from off‐targeting effects that could be overcome using vectors 247–253 . In this section, we discuss the use of liposomes for the targeted delivery of the CRISPR/Cas9 system in cancer treatment.…”

Section: Liposomes and Gene Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Nanoliposomes as nonviral vectors in cancer gene therapy

Yildiz,

Entezari,

Paskeh

et al. 2024

MedComm

View full text Add to dashboard Cite

Nonviral vectors, such as liposomes, offer potential for targeted gene delivery in cancer therapy. Liposomes, composed of phospholipid vesicles, have demonstrated efficacy as nanocarriers for genetic tools, addressing the limitations of off‐targeting and degradation commonly associated with traditional gene therapy approaches. Due to their biocompatibility, stability, and tunable physicochemical properties, they offer potential in overcoming the challenges associated with gene therapy, such as low transfection efficiency and poor stability in biological fluids. Despite these advancements, there remains a gap in understanding the optimal utilization of nanoliposomes for enhanced gene delivery in cancer treatment. This review delves into the present state of nanoliposomes as carriers for genetic tools in cancer therapy, sheds light on their potential to safeguard genetic payloads and facilitate cell internalization alongside the evolution of smart nanocarriers for targeted delivery. The challenges linked to their biocompatibility and the factors that restrict their effectiveness in gene delivery are also discussed along with exploring the potential of nanoliposomes in cancer gene therapy strategies by analyzing recent advancements and offering future directions.

show abstract

Section: Liposomes and Gene Deliverymentioning

confidence: 99%

Section: Liposomes and Gene Deliverymentioning

confidence: 99%

Nanoliposomes as nonviral vectors in cancer gene therapy

Yildiz,

Entezari,

Paskeh

et al. 2024

MedComm

View full text Add to dashboard Cite

show abstract

“…Currently, genetic engineering-based technologies have been anticipated for the treatment or therapy of TNBC that is able to target any molecule in the pretentious part, as well as knockout and silent gene aberration/alternations [ 14 , 226 ]. However, DNA binding domain-dependent orthodox techniques, specifically zinc finger nuclease (ZFNs) and transcriptional activator-like effector nuclease (TALENs) gained exceptional importance in genetically engineered breast tissue organoids, cellular carcinoma models, and gene therapy investigations [ 14 , 227 ]. However, due to their intricacy and inefficient approaches, an extensive application of this therapy has been constrained [ 43 ].…”

Section: Ongoing Treatments For Triple-negative Breast Cancermentioning

confidence: 99%

Nanomaterial-assisted CRISPR gene-engineering – A hallmark for triple-negative breast cancer therapeutics advancement

Farheen¹,

Hosmane²,

Zhao³

et al. 2022

Materials Today Bio

View full text Add to dashboard Cite

“…A variety of studies have applied CRISPR-Cas systems for effectively targeting different genes and have managed to prove the potential treatment ability for initiation or progression of lung cancer, 64 breast cancer, 65 , 66 and many other types of cancers. 67–69 Meanwhile, the CRISPR-Cas system has been harnessed to serve as a powerful tool with the ability of unbiased screening of precision medicine including identification of new drug targets, biomarkers, and elucidation of mechanisms leading to drug resistance. 70–72 In short, there are tremendous potential applications for CRISPR-Cas and their derivative systems (i.e.…”

Section: Preclinical Testsmentioning

confidence: 99%

Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics

Liu

Jiang

et al. 2021

Precision Clinical Medicine

View full text Add to dashboard Cite

Clustered regularly interspaced short palindromic repeats-CRISPR associated systems (Cas) are efficient tools for targeting specific genes for laboratory research, agricultural engineering, biotechnology, and human disease treatment. Cas9, by far the most extensively used gene-editing nuclease, has shown great promise for the treatment of hereditary diseases, viral infection, cancers and so on. Recent reports have revealed that some other types of CRISPR-Cas systems may also have surprising potential to join the fray as gene-editing tools for various applications. Despite the fast progress in basic researches and clinical tests, some underlying problems present continuous, significant challenges, such as editing efficiency, relative difficulty in delivery, off-target effects, immunogenicity, etc. This article summarizes the applications of CRISPR-Cas from bench to bedside and highlights the current obstacles that may limit the usage of CRISPR-Cas systems as gene-editing tool-kits in precision medicine and offer some viewpoints that may help to tackle these challenges and facilitate technical development. CRISPR-Cas systems, as a powerful gene-editing approach, will offer great hopes in clinical treatments for many individuals with currently incurable diseases.

show abstract

Research on CRISPR/system in major cancers and its potential in cancer treatments

Cited by 4 publications

References 63 publications

Nanoliposomes as nonviral vectors in cancer gene therapy

Nanoliposomes as nonviral vectors in cancer gene therapy

Nanomaterial-assisted CRISPR gene-engineering – A hallmark for triple-negative breast cancer therapeutics advancement

Applications and challenges of CRISPR-Cas gene-editing to disease treatment in clinics

Contact Info

Product

Resources

About